Abstract
Quantitative Structure Activity Relationship (QSAR) modeling has been traditionally applied as an evaluative approach, i.e., with the focus on developing retrospective and explanatory models of existing data. Model extrapolation was considered if only in hypothetical sense in terms of potential modifications of known biologically active chemicals that could improve compounds activity. This critical review re-examines the strategy and the output of the modern QSAR modeling approaches. We provide examples and arguments suggesting that current methodologies may afford robust and validated models capable of accurate prediction of compound properties for molecules not included in the training sets. We discuss a data-analytical modeling workflow developed in our laboratory that incorporates modules for combinatorial QSAR model development (i.e., using all possible binary combinations of available descriptor sets and statistical data modeling techniques), rigorous model validation, and virtual screening of available chemical databases to identify novel biologically active compounds. Our approach places particular emphasis on model validation as well as the need to define model applicability domains in the chemistry space. We present examples of studies where the application of rigorously validated QSAR models to virtual screening identified computational hits that were confirmed by subsequent experimental investigations. The emerging focus of QSAR modeling on target property forecasting brings it forward as predictive, as opposed to evaluative, modeling approach.
Keywords: QSAR-quantitative structure activity relationships, combi-QSAR-combinatorial QSAR, kNN - k nearest neighbors, SA -simulating annealing, PLS - partial least squares
Current Pharmaceutical Design
Title: Predictive QSAR Modeling Workflow, Model Applicability Domains, and Virtual Screening
Volume: 13 Issue: 34
Author(s): Alexander Tropsha and Alexander Golbraikh
Affiliation:
Keywords: QSAR-quantitative structure activity relationships, combi-QSAR-combinatorial QSAR, kNN - k nearest neighbors, SA -simulating annealing, PLS - partial least squares
Abstract: Quantitative Structure Activity Relationship (QSAR) modeling has been traditionally applied as an evaluative approach, i.e., with the focus on developing retrospective and explanatory models of existing data. Model extrapolation was considered if only in hypothetical sense in terms of potential modifications of known biologically active chemicals that could improve compounds activity. This critical review re-examines the strategy and the output of the modern QSAR modeling approaches. We provide examples and arguments suggesting that current methodologies may afford robust and validated models capable of accurate prediction of compound properties for molecules not included in the training sets. We discuss a data-analytical modeling workflow developed in our laboratory that incorporates modules for combinatorial QSAR model development (i.e., using all possible binary combinations of available descriptor sets and statistical data modeling techniques), rigorous model validation, and virtual screening of available chemical databases to identify novel biologically active compounds. Our approach places particular emphasis on model validation as well as the need to define model applicability domains in the chemistry space. We present examples of studies where the application of rigorously validated QSAR models to virtual screening identified computational hits that were confirmed by subsequent experimental investigations. The emerging focus of QSAR modeling on target property forecasting brings it forward as predictive, as opposed to evaluative, modeling approach.
Export Options
About this article
Cite this article as:
Tropsha Alexander and Golbraikh Alexander, Predictive QSAR Modeling Workflow, Model Applicability Domains, and Virtual Screening, Current Pharmaceutical Design 2007; 13 (34) . https://dx.doi.org/10.2174/138161207782794257
DOI https://dx.doi.org/10.2174/138161207782794257 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Chemokines and Chemokine Receptors: Potential Therapeutic Targets in Multiple Sclerosis
Current Drug Targets - Inflammation & Allergy Therapeutic Potential of Natural Compounds that Regulate the Activity of Protein Kinase C
Current Medicinal Chemistry Formulation Development of Folic Acid Conjugated PLGA Nanoparticles for Improved Cytotoxicity of Caffeic Acid Phenethyl Ester
Pharmaceutical Nanotechnology Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Nanomedicine: A New Frontier in Cancer Therapeutics
Current Drug Delivery Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Editorial [Hot Topic: Evolving Drug Targets in DNA Base Excision Repair for Cancer Therapy (Guest Editor: Srinivasan Madhusudan)]
Current Molecular Pharmacology Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry P-Glycoprotein - Implications of Metabolism of Neoplastic Cells and Cancer Therapy
Current Cancer Drug Targets VS-5584 Inhibits Human Osteosarcoma Cells Growth by Induction of G1- phase Arrest through Regulating PI3K/mTOR and MAPK Pathways
Current Cancer Drug Targets Recent Advances in Medicinal Applications of Coinage-Metal (Cu and Ag) N-Heterocyclic Carbene Complexes
Current Topics in Medicinal Chemistry Investigation of the Antiproliferative Action of the Quinoline Alkaloids Kokusaginine and Skimmianine on Human Cell Lines
Current Signal Transduction Therapy DNA Damage Response Pathways and Cell Cycle Checkpoints in Colorectal Cancer: Current Concepts and Future Perspectives for Targeted Treatment
Current Cancer Drug Targets Endothelin-1 and Angiogenesis in Cancer
Current Vascular Pharmacology PRL-3, An Emerging Marker of Carcinogenesis, Is Strongly Associated with Poor Prognosis
Anti-Cancer Agents in Medicinal Chemistry PKC Delta and Epsilon in Drug Targeting and Therapeutics
Recent Patents on DNA & Gene Sequences Current Research on Opioid Receptor Function
Current Drug Targets TRPC Channels and Their Splice Variants are Essential for Promoting Human Ovarian Cancer Cell Proliferation and Tumorigenesis
Current Cancer Drug Targets